Metis Global Partners LLC Has $22.53 Million Stake in AbbVie Inc. $ABBV

Metis Global Partners LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,286 shares of the company’s stock after selling 4,727 shares during the quarter. AbbVie accounts for 0.5% of Metis Global Partners LLC’s investment portfolio, making the stock its 27th biggest holding. Metis Global Partners LLC’s holdings in AbbVie were worth $22,526,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the period. Norges Bank purchased a new position in AbbVie during the second quarter valued at approximately $4,288,200,000. Finally, Raymond James Financial Inc. increased its stake in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Berenberg Bank set a $275.00 target price on AbbVie in a research note on Tuesday, January 20th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales and upbeat execution: AbbVie reported record net sales and raised forward visibility after Q4 results, with analysts (e.g., Cantor Fitzgerald) reiterating bullish views and a $250 target tied to Skyrizi and Rinvoq strength. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Korean post‑marketing Rinvoq study completed — bolsters real‑world evidence for Rinvoq in immunology, supporting long‑term revenue growth for the immunology franchise. Real‑world data can aid uptake and payer discussions. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Neutral Sentiment: Analyst notes and reports are reframing valuation: recent analyst reports (Argus, other coverage) review AbbVie’s pipeline and valuation after strong results — useful for context but not a consensus catalyst. Analyst Report: AbbVie Inc
• Neutral Sentiment: Pipeline updates (elezanumab phase 2): AbbVie updated a Phase 2 study in acute cervical spinal cord injury — monitor readouts for potential long‑term upside but no immediate revenue impact. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Small analyst PT trim from Evercore ISI: Evercore trimmed its price target modestly but kept an Outperform rating — suggests confidence in fundamentals despite nearer‑term headwinds. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Legal and policy risk: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — outcome could materially affect Botox pricing and margins. This litigation creates near‑term uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure in immunology: J&J’s heavy Tremfya ad spend is intensifying competition for AbbVie’s Rinvoq and Skyrizi, which could pressure market share and growth trajectories in key indications. J&J’s Tremfya roars 2026 ad spend trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: U.S. operational changes and Medicaid concessions: AbbVie is reshaping U.S. operations and making Medicaid concessions to manage pricing headwinds — could weigh on near‑term U.S. margins even as it targets long‑term growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

AbbVie Stock Performance

ABBV opened at $227.57 on Friday. The firm has a market cap of $402.20 billion, a P/E ratio of 96.43, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The business has a 50 day moving average price of $223.45 and a 200 day moving average price of $220.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the company posted $2.16 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.